Latest Chronic Pain News
However, some experts who expressed concerns about the study published in the journal Science Translational Medicine pointed out that it was not a clinical trial, which is the gold standard for medical research, The New York Times reported.
The findings by the team at McGill University in Montreal are based on observations of patients, an analysis of a large patient database and an animal study.
The study results suggest we "need to think further about how to treat our patients,” lead investigator Dr. Luda Diatchenko, a professor who specializes in human pain genetics, told the Times.
The research is “intriguing, but requires further study,” Dr. Steven Atlas, director of primary care practice-based research and quality improvement at Massachusetts General Hospital, told the Times.
That opinion was echoed by Dr. Bruce Vrooman, a pain specialist at Dartmouth Hitchcock Medical Center in New Hampshire. But Vrooman also told the Times that the study was “impressive in its scope” and added that if the findings hold up in a clinical trial, it could “force reconsideration of how we treat acute pain."
The study represents a "paradigm shift," Dr. Thomas Buchheit, director of the regenerative pain therapies program at Duke University, told the Times.
“There is this unspoken rule: If it hurts, take an anti-inflammatory, and if it still hurts, put a steroid on it,” he said. But this study shows that “we have to think of healing, and not suppression of inflammation.”
Visit the National Library of Medicine for more on back pain.
By Robert Preidt HealthDay Reporter
Copyright © 2021 HealthDay. All rights reserved.